Literature DB >> 20478998

Pleiotropic role for MYCN in medulloblastoma.

Fredrik J Swartling1, Matthew R Grimmer, Christopher S Hackett, Paul A Northcott, Qi-Wen Fan, David D Goldenberg, Jasmine Lau, Selma Masic, Kim Nguyen, Slava Yakovenko, Xiao-Ning Zhe, Heather C Flynn Gilmer, Rodney Collins, Mai Nagaoka, Joanna J Phillips, Robert B Jenkins, Tarik Tihan, Scott R Vandenberg, C David James, Kohichi Tanaka, Michael D Taylor, William A Weiss, Louis Chesler.   

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor of childhood. Sonic Hedgehog (SHH) signaling drives a minority of MB, correlating with desmoplastic pathology and favorable outcome. The majority, however, arises independently of SHH and displays classic or large cell anaplastic (LCA) pathology and poor prognosis. To identify common signaling abnormalities, we profiled mRNA, demonstrating misexpression of MYCN in the majority of human MB and negligible expression in normal cerebella. We clarified a role in pathogenesis by targeting MYCN (and luciferase) to cerebella of transgenic mice. MYCN-driven MB showed either classic or LCA pathologies, with Shh signaling activated in approximately 5% of tumors, demonstrating that MYCN can drive MB independently of Shh. MB arose at high penetrance, consistent with a role for MYCN in initiation. Tumor burden correlated with bioluminescence, with rare metastatic spread to the leptomeninges, suggesting roles for MYCN in both progression and metastasis. Transient pharmacological down-regulation of MYCN led to both clearance and senescence of tumor cells, and improved survival. Targeted expression of MYCN thus contributes to initiation, progression, and maintenance of MB, suggesting a central role for MYCN in pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20478998      PMCID: PMC2867210          DOI: 10.1101/gad.1907510

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  75 in total

1.  Loss of heterozygosity at locus F13B on chromosome 1q in human medulloblastoma.

Authors:  J A Kraus; A Koch; S Albrecht; A Von Deimling; O D Wiestler; T Pietsch
Journal:  Int J Cancer       Date:  1996-07-03       Impact factor: 7.396

2.  Sporadic medulloblastomas contain PTCH mutations.

Authors:  C Raffel; R B Jenkins; L Frederick; D Hebrink; B Alderete; D W Fults; C D James
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1.

Authors:  K Tanaka; K Watase; T Manabe; K Yamada; M Watanabe; K Takahashi; H Iwama; T Nishikawa; N Ichihara; T Kikuchi; S Okuyama; N Kawashima; S Hori; M Takimoto; K Wada
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

4.  Altered neural cell fates and medulloblastoma in mouse patched mutants.

Authors:  L V Goodrich; L Milenković; K M Higgins; M P Scott
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

5.  N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.

Authors:  Jessica D Kessler; Hiroshi Hasegawa; Sonja N Brun; Brian A Emmenegger; Zeng-Jie Yang; John W Dutton; Fan Wang; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

6.  Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.

Authors:  W D Thomas; J Chen; Y R Gao; B Cheung; J Koach; E Sekyere; M D Norris; M Haber; T Ellis; B Wainwright; G M Marshall
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

7.  The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.

Authors:  Paul A Northcott; Africa Fernandez-L; John P Hagan; David W Ellison; Wesia Grajkowska; Yancey Gillespie; Richard Grundy; Timothy Van Meter; James T Rutka; Carlo M Croce; Anna Marie Kenney; Michael D Taylor
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Ly-1 antibody reactive clone is an important nucleolar protein for control of self-renewal and differentiation in embryonic stem cells.

Authors:  Hui Li; Beibei Wang; Acong Yang; Rui Lu; Weicheng Wang; Yang Zhou; Guilai Shi; Sung Won Kwon; Yingming Zhao; Ying Jin
Journal:  Stem Cells       Date:  2009-06       Impact factor: 6.277

9.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.

Authors:  Stefan Pfister; Marc Remke; Axel Benner; Frank Mendrzyk; Grischa Toedt; Jörg Felsberg; Andrea Wittmann; Frauke Devens; Nicolas U Gerber; Stefan Joos; Andreas Kulozik; Guido Reifenberger; Stefan Rutkowski; Otmar D Wiestler; Bernhard Radlwimmer; Wolfram Scheurlen; Peter Lichter; Andrey Korshunov
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).

Authors:  H A Rogers; S Miller; J Lowe; M-A Brundler; B Coyle; R G Grundy
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

View more
  87 in total

1.  Novel cell lines established from pediatric brain tumors.

Authors:  Jingying Xu; Anat Erdreich-Epstein; Ignacio Gonzalez-Gomez; Elizabeth Y Melendez; Goar Smbatyan; Rex A Moats; Michael Rosol; Jaclyn A Biegel; C Patrick Reynolds
Journal:  J Neurooncol       Date:  2011-11-27       Impact factor: 4.130

2.  Adding more to the Myc story.

Authors:  Meera Swami
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

Review 3.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

Review 4.  Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Authors:  Jasmine Lau; Christin Schmidt; Shirley L Markant; Michael D Taylor; Robert J Wechsler-Reya; William A Weiss
Journal:  Childs Nerv Syst       Date:  2012-04       Impact factor: 1.475

Review 5.  Development and cancer of the cerebellum.

Authors:  Mary E Hatten; Martine F Roussel
Journal:  Trends Neurosci       Date:  2011-03       Impact factor: 13.837

Review 6.  Family matters: How MYC family oncogenes impact small cell lung cancer.

Authors:  Johannes Brägelmann; Stefanie Böhm; Matthew R Guthrie; Gurkan Mollaoglu; Trudy G Oliver; Martin L Sos
Journal:  Cell Cycle       Date:  2017-07-24       Impact factor: 4.534

7.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Authors:  Fredrik J Swartling; Vasil Savov; Anders I Persson; Justin Chen; Christopher S Hackett; Paul A Northcott; Matthew R Grimmer; Jasmine Lau; Louis Chesler; Arie Perry; Joanna J Phillips; Michael D Taylor; William A Weiss
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

Review 8.  Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Brain Pathol       Date:  2011-07-07       Impact factor: 6.508

Review 9.  Medulloblastoma development: tumor biology informs treatment decisions.

Authors:  Vidya Gopalakrishnan; Rong-Hua Tao; Tara Dobson; William Brugmann; Soumen Khatua
Journal:  CNS Oncol       Date:  2015

Review 10.  Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo.

Authors:  Brandon Kocher; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2013-04-12       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.